Original Research| Volume 131, P27-36, May 2020

Download started.


Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

Published:April 07, 2020DOI:


      • Prognosis of patients with advanced non–small-cell lung cancer (NSCLC) is poor.
      • Few options beyond platinum-based chemo and immunotherapy in non-squamous (ns) NSCLC.
      • Phase III trial of bevacizumab-paclitaxel (wPB) or docetaxel in 2nd/3rd line nsNSCLC.
      • wPB improved progression-free survival and objective response rate.
      • Safety profile was manageable and Quality of Life was preserved with wPB.



      Second-line chemotherapy regimens have demonstrated poor benefit after failure of platinum-based chemotherapy in advanced non-squamous non–small-cell lung cancer (nsNSCLC).


      In this multicentre, open-label phase III trial, patients with advanced nsNSCLC treated with one or two prior lines, including one platinum-based doublet, were centrally randomised to receive 90 mg/m2 of paclitaxel (D1, D8, D15) plus 10 mg/kg of bevacizumab (D1, D15) every 28 days or docetaxel (75 mg/m2) every 21 days; crossover was allowed after disease progression. Primary end-point was progression-free survival (PFS). registration number: NCT01763671.


      One hundred sixty six patients were randomised (paclitaxel plus bevacizumab: 111, docetaxel: 55). The median PFS was longer in patients receiving paclitaxel plus bevacizumab than in patients receveing docetaxel [5·4 months versus 3·9 months, adjusted hazard ratio (HR) 0·61 (95% confidence interval [CI]: 0·44–0·86); p = 0·005]. Objective response rates (ORRs) were 22·5% (95% CI: 14·8–30·3) and 5·5% (95% CI: 0·0–11·5) (p = 0·006), respectively. Median overall survivals were similar (adjusted HR 1·17; p = 0·50). Crossover occurred in 21 of 55 (38·2%) docetaxel-treated patients. Grade III-IV adverse events (AEs) were reported in 45·9% and 54·5% of patients treated with paclitaxel and bevacizumab or docetaxel, respectively (p = NS), including neutropenia (19·3% versus 45·4%), neuropathy (8·3% versus 0·0%) and hypertension (7·3% versus 0·0%). Three patients died due to treatment-related AEs (1·8% in each group).


      Weekly paclitaxel plus bevacizumab as second- or third-line improves PFS and ORR compared with docetaxel in patients with nsNSCLC, with an acceptable safety profile. These results place weekly paclitaxel plus bevacizumab as a valid option in this population.

      Clinical trials registration number Identifier: NCT01763671.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Borghaei H.
        • Paz-Ares L.
        • Horn L.
        • et al.
        Nivolumab versus docetaxel in advanced nonsquamousnon-small-cell lung cancer.
        N Engl J Med. 2015; 373: 1627-1639
        • Herbst R.S.
        • Baas P.
        • Kim D.W.
        • et al.
        Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
        Lancet. 2016; 387: 1540-1550
        • Rittmeyer A.
        • Barlesi F.
        • Waterkamp D.
        • et al.
        Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentrerandomised controlled trial.
        Lancet. 2017; 389: 255-265
        • Gandhi L.
        • Rodríguez-Abreu D.
        • Gadgeel S.
        • et al.
        Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer.
        N Engl J Med. 2018; 378: 2078-2092
        • Socinski M.
        • Jotte R.M.
        • Cappuzzo F.
        • et al.
        Atezolizumab for first-line treatment of metastatic nonsquamousNSCLC.
        N Engl J Med. 2018; 378: 2288-2301
        • Leighl N.B.
        Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.
        CurrOncol. 2012; 19: S52-S58
        • Ettinger D.S.
        • Akerley W.
        • Borghaei H.
        • et al.
        Non-small cell lung cancer.
        J Natl Compr Canc Netw. 2012; 10: 1236-1271
        • Peters S.
        • Adjei A.A.
        • Gridelli C.
        • Reck M.
        • Kerr K.
        • Felip E.
        • ESMO Guidelines Working Group
        Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2012; Suppl7: vii56-vii64
        • Garon E.B.
        • Ciuleanu T.E.
        • Arrieta O.
        • et al.
        Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
        Lancet. 2014; 384: 665-673
        • Reck M.
        • Kaiser R.
        • Mellemgaard A.
        • et al.
        Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
        Lancet Oncol. 2014; 15: 143-155
        • Sandler A.
        • Gray R.
        • Perry M.C.
        • et al.
        Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
        N Engl J Med. 2006; 355: 2542-2550
        • Miller K.
        • Wang M.
        • Gralow J.
        • et al.
        Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
        N Engl J Med. 2007; 357: 2666-2676
        • Miles D.W.
        • Chan A.
        • Dirix L.Y.
        • et al.
        Phase III study of bevacizumabplus docetaxelcompared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic breast cancer.
        J ClinOncol. 2010; 28: 3239-3247
        • Robert N.J.
        • Diéras V.
        • Glaspy J.
        • et al.
        RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer.
        J ClinOncol. 2011; 29: 1252-1260
        • Le Moulec S.
        • Hadoux J.
        • Gontier E.
        • et al.
        Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
        Bull Cancer. 2013; 100: 30-37
        • Habib S.
        • Delourme J.
        • Dhalluin X.
        • et al.
        Bevacizumab and weekly paclitaxel for non-squamous non-small cell lung cancer patients: a retrospective study.
        Lung Canc. 2013; 80: 197-202
        • Hilberg F.
        • Roth G.J.
        • Krssak M.
        • et al.
        BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
        Canc Res. 2008; 68: 4774-4782
        • Spratlin J.L.
        • Cohen R.B.
        • Eadens M.
        • et al.
        Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
        J ClinOncol. 2010; 28: 780-787
        • Planchard D.
        • Popat S.
        • Kerr K.
        • et al.
        Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2018 Oct 1; 29: iv192-iv237
        • Quoix E.
        • Zalcman G.
        • Ostern J.P.
        • et al.
        Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
        Lancet. 2011; 378: 1079-1088
        • Pardoll D.M.
        The blockade of immune checkpoints in cancer immunotherapy.
        Nat Rev Canc. 2012; 12: 252-264
        • Camerini A.
        • Chella A.
        • Mazzoni F.
        • et al.
        First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey.t al.
        J Chemother. 2017; 29: 38-41
        • Socinski M.A.
        • Jotte R.M.
        • Cappuzzo F.
        • et al.
        Atezolizumab for first-line treatment of metastatic nonsquamousNSCLC.
        N Engl J Med. 2018 Jun 14; 378: 2288-2301
        • Bilger G.
        • Boré P.
        • Valery S.
        • et al.
        Efficacy of weekly paclitaxel-bevacizumab combination in advanced nonsquamous non-small cell lung cancer (NSCLC) : a retrospective multicentric study.
        Ann Oncol. 2019; 30: v602-v660
        • Reck
        • et al.
        Ann Oncol. 2019; 30: xi16-xi32